The atopic dermatitis (AD) market is on track to reach $16.7 billion across mature markets by 2030, according to data and analytics company GlobalData. 19 September 2024
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Danish dermatology specialist LEO Pharma has presented a range of new population-level and physician-reported data on the prevalence, severity and treatment of moderate to severe chronic hand eczema (CHE). 5 September 2024
Biocon Biologics has signed a settlement and license agreement with Johnson & Johnson that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara (ustekinumab), in Europe, the UK, Canada, and Japan. 3 September 2024
South Korea’s Celltrion yesterday announced the European Commission (EC) approval for the use of SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases. 27 August 2024
Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12-week period of the ASCEND trial. 23 August 2024
San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) yesterday announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on August 13, 2024. 15 August 2024
Shares of American dermatology company Verrica Pharmaceuticals had a roller-coaster start to the day after announcing what it called positive trial results. 14 August 2024
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
The US subsidiary of South Korea’s Celltrion announced its US Food and Drug Administration (FDA)-approved biosimilar adalimumab-aaty has been added to the Costco member prescription program. 14 August 2024
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
BioNTech released positive top-line data from the ongoing Phase II clinical trial in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. 30 July 2024
California’s Arcutis Biotherapeutics, a biopharma developing innovations in immuno-dermatology, has announced the US commercial launch of Zoryve (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age six years. 30 July 2024
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines for approval at its July 2024 meeting. 26 July 2024
“Circle of Goodness,” one of Russia’s largest public funds, specializing on procurements of drugs for children with rare diseases, will begin procurements of the US drug Vyjuvek (beremagen heperpavec), which is designed for patients with epidermolysis bullosa (butterfly syndrome), reports The Pharma Letter’s local correspondent. 25 July 2024
Indian drug major Dr Reddy’s Laboratories has signed a commercialization deal with Australian firm Hatchtech for its innovative prescription head lice product Xeglyze Lotion. 14 September 2015
Aclaris Therapeutics and Rigel Pharmaceutical have entered into an exclusive, worldwide license agreement for the development and commercialization of Rigel’s JAK inhibitor compounds for the treatment of alopecia areata and other dermatological conditions. 10 September 2015
The US Food and Drug Administration has issued a warning about reports of severe allergic reactions and herpes zoster (shingles) associated with the use of Picato gel (ingenol mebutate), which is used to treat actinic keratosis. 22 August 2015
Indian drugmaker Sun Pharmaceutical Industries yesterday announced that the US Food and Drug Administration has approved its supplemental New Drug Application (sNDA) for Ximino (minocycline HCl) extended-release capsules. 20 August 2015
US biotech company Amgen has reached an agreement to pay $71 million to 48 US states and the District of Columbia over the marketing of Enbrel (etanercept) and Aranesp (darbepoetin alfa). 19 August 2015
KYTHERA Biopharmaceuticals has submitted a Marketing Authorization Application (MAA) in the European Union, seeking approval for ATX-101 (deoxycholic acid) injection. 18 August 2015
The US Food and Drug Administration has approved German pharma major Bayer’s Finacea (azelaic acid) Foam, 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea 4 August 2015
Amarantus BioScience on Monday said it has partnered with the US Army Institute of Surgical Research and Rutgers to collaborate on developing a treatment of deep burn wounds in adults. 3 August 2015
AbbVie says that its mega blockbuster drug Humira (adalimumab) is now approved in the European Union for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa). 3 August 2015
Hong Kong-based Bloomage BioTechnology Corp has entered a strategic cooperation with the South Korean biotech company Medytox to establish a joint venture, to be called Medybloom, to develop and promote Type A Botulinum Toxin business in China. 30 July 2015
Almirall has announced the closing of a $15 million in Series C equity investment in privately-held US firm Suneva Medical, an innovative aesthetics leader that markets Bellafill. 29 July 2015
Almirall has released solid first-half 2015 performance in line to achieve yearly guidance, with like for like growth of net sales up 4.0% and earnings before interest, taxes, depreciation and amortization (EBITDA) rising 35.5% driven by dermatology. 28 July 2015
KYTHERA Biopharmaceuticals has received authorization from drug regulator Health Canada to market Belkyra (deoxycholic acid) “for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat (SMF) in adults.” 27 July 2015
The National Institute for Health and Care Excellence (NICE) has issued final guidance for Vargatef (nintedanib) from German family-owned pharma major Boehringer Ingelheim. 22 July 2015
US pharma giant Johnson & Johnson says that its guselkumab showed improvements in primary and secondary endpoints versus placebo and against AbbVie’s Humira (adalimumab) in plaque psoriasis at Phase IIb. 10 July 2015
USA-based Anacor Pharmaceuticals has amended its distribution and commercialization agreement with Sandoz, a subsidiary of Swiss pharma giant Novartis. 29 June 2015
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended extending the use of us drugmaker AbbVie’s Humira (adalimumab) to include treatment of adults with active moderate to severe hidradenitis suppurativa (acne inversa), who have failed to respond to conventional systemic treatments. 26 June 2015
US aesthetic medicine specialist KYTHERA Biopharmaceuticals (Nasdaq: KYTH) on Friday announced the US availability of Kybella (deoxycholic acid) injection. 20 June 2015
Botox maker Allergan has reached a definitive agreement to acquire KYTHERA Biopharmaceuticals (Nasdaq: KYTH), a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. 17 June 2015